3 Biotech Stocks to Sell in October This year will probably go down as the roughest year for investors since the financial recession in 2008. The SP 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equities market. Hence, investors are scrambling to streamline their portfolios. In doing so, they might want to think about some biotech stocks to sell. Biotech stocks have typically been among the most risky investments. These firms spend a ton of money on research and development and offer little to no assurance that their pipeline will ever reach the commercialization stage. Additionally, most of these companies operate at a loss for years, which has irked investors of late. Hence, it’s probably best to sell off many of the non-performing biotech stocks before more significant losses arrive. That said, it’s true that the industry is set for incredible growth over the long term. The trick for investors is to perform extensive due diligence before wagering on biotech stocks.